Literature DB >> 34663949

Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy.

Roseanna C Wheatley1,2, Elaine Kilgour3, Timothy Jacobs4, Angela Lamarca1,2, Richard A Hubner1,2, Juan W Valle1,2, Mairéad G McNamara5,6.   

Abstract

Biliary tract cancers, including intra- and extra-hepatic cholangiocarcinoma as well as gallbladder cancer, are associated with poor prognosis and the majority of patients present with advanced-stage, non-resectable disease at diagnosis. Biliary tract cancer may develop through an accumulation of genetic and epigenetic alterations and can be influenced by microbial exposure. Furthermore, the liver and biliary tract are exposed to the gastrointestinal microbiome through the gut-liver axis. The availability of next-generation sequencing technology has led to an increase in studies investigating the relationship between microbiota and human disease. In particular, the interplay between the microbiome, the tumour micro-environment and response to systemic therapy is a prospering area of interest. Given the poor outcomes for patients with biliary tract cancer, this emerging field of research, through which new biomarkers may be identified, offers potential as a tool for early diagnosis, prognostication or even as a future therapeutic target. This review summarises the available evidence on the microbiome environment in patients with biliary tract cancer, including a discussion around confounding factors, implications for therapy and proposed future directions.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34663949      PMCID: PMC8888758          DOI: 10.1038/s41416-021-01583-8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  73 in total

1.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

2.  Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

Authors:  S D Taylor-Robinson; M B Toledano; S Arora; T J Keegan; S Hargreaves; A Beck; S A Khan; P Elliott; H C Thomas
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

Review 3.  Roles of liver fluke infection as risk factor for cholangiocarcinoma.

Authors:  Paiboon Sithithaworn; Puangrat Yongvanit; Kunyarat Duenngai; Nadda Kiatsopit; Chawalit Pairojkul
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-01-10       Impact factor: 7.027

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

Review 5.  Biliary tract cancer.

Authors:  Juan W Valle; R Katie Kelley; Bruno Nervi; Do-Youn Oh; Andrew X Zhu
Journal:  Lancet       Date:  2021-01-30       Impact factor: 79.321

Review 6.  Clinical presentation, diagnosis and staging of cholangiocarcinoma.

Authors:  Alejandro Forner; Gianpaolo Vidili; Marco Rengo; Luis Bujanda; Mariano Ponz-Sarvisé; Angela Lamarca
Journal:  Liver Int       Date:  2019-03-25       Impact factor: 5.828

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

8.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

9.  Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

Authors:  Angela Lamarca; Daniel H Palmer; Harpreet Singh Wasan; Paul J Ross; Yuk Ting Ma; Arvind Arora; Stephen Falk; Roopinder Gillmore; Jonathan Wadsley; Kinnari Patel; Alan Anthoney; Anthony Maraveyas; Tim Iveson; Justin S Waters; Claire Hobbs; Safia Barber; W David Ryder; John Ramage; Linda M Davies; John A Bridgewater; Juan W Valle
Journal:  Lancet Oncol       Date:  2021-03-30       Impact factor: 41.316

10.  Estimated Projection of US Cancer Incidence and Death to 2040.

Authors:  Lola Rahib; Mackenzie R Wehner; Lynn M Matrisian; Kevin T Nead
Journal:  JAMA Netw Open       Date:  2021-04-01
View more
  3 in total

1.  The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC).

Authors:  Roseanna C Wheatley; Juan W Valle; Mairéad G McNamara
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

Review 2.  Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances.

Authors:  Hao Qin; Baowen Yuan; Wei Huang; Yan Wang
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

3.  Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis.

Authors:  Wence Zhou; Xinlong Chen; Qigang Fan; Haichuan Yu; Wenkai Jiang
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.